Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp. a clinical-stage biopharmaceutical company develops therapeutics and vaccines to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology rare disease infectious disease and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection autoimmunity and cancer including TNX-1500 a humanized monoclonal antibody targeting CD40-ligand being developed to treat autoimmune conditions. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801 a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; and TNX-102 SL a CNS product candidate to treat Long COVID a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain neurologic psychiatric and addiction conditions including TNX-102 SL which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300 a recombinant protein enzyme to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham New Jersey.